1. Home
  2. GNLX vs XGN Comparison

GNLX vs XGN Comparison

Compare GNLX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

BUY

Current Price

$2.53

Market Cap

110.4M

Sector

Health Care

ML Signal

BUY

Logo Exagen Inc.

XGN

Exagen Inc.

SELL

Current Price

$8.08

Market Cap

110.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GNLX
XGN
Founded
2001
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
110.7M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
GNLX
XGN
Price
$2.53
$8.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
★ $18.83
$10.14
AVG Volume (30 Days)
209.7K
★ 260.2K
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 9.47
N/A
EPS
N/A
★ N/A
Revenue
★ $8,000.00
N/A
Revenue This Year
N/A
$11.02
Revenue Next Year
N/A
$10.28
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.29
$2.59
52 Week High
$8.54
$12.23

Technical Indicators

Market Signals
Indicator
GNLX
XGN
Relative Strength Index (RSI) 47.29 52.60
Support Level $2.32 $6.83
Resistance Level $2.93 $8.89
Average True Range (ATR) 0.11 0.42
MACD 0.01 -0.09
Stochastic Oscillator 40.00 22.22

Price Performance

Historical Comparison
GNLX
XGN

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: